Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Don't wash that baby! study tests if keeping vernix on prevents eczema

NCT ID NCT07333378

Prevention Sponsor: Pontificia Universidad Catolica de Chile Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 28, 2026 · Updated 5 times

Summary

This study tests whether leaving the white, creamy coating (vernix caseosa) on a newborn's skin for at least 24 hours after birth can prevent eczema (atopic dermatitis) during the first year of life. Over 1,300 mother-infant pairs in Chile will be randomly assigned to either keep the vernix on or have it washed off as usual. Researchers will track how many babies develop eczema and measure skin health and microbiome differences.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vernix caseosa (the natural white coating on newborns)
What this could lead to
If it works, this simple, no-cost change in newborn care could reduce eczema risk in infants worldwide.
What could go wrong
This is a single study in Chile; results may not apply everywhere. The intervention is subtle, so the effect may be small or hard to detect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,383 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 days and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * pregnant mother aged 18 and older, who is able to provide informed consent for participation * delivery of a healthy, singleton newborn (vaginal or cesarean) at one of the study sites. * parents are able and willing to comply with the study schedule and procedures Exclusion Criteria: * birthweight \<2000 g * prematurity younger than 34 weeks of gestation * multiple gestation / multiple births * maternal HIV-positivity * clinical and/or laboratory diagnosis of chorioamnionitis. * need for neonatal hospitalization or presence of an acute illness (e.g., neonatal respiratory distress syndrome) within the first 24 hours of life. * severe and generalized congenital skin disorder (e.g., congenital ichthyosis).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cellulitis Eczema staphylococcal infection atopic eczema prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clínica San Carlos de Apoquindo

    Las Condes, RM, Chile

  • Hospital Clínico Universidad Católica

    Santiago, RM, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.